Stryker Co. (NYSE:SYK) Shares Bought by Bryn Mawr Capital Management LLC

Bryn Mawr Capital Management LLC raised its stake in shares of Stryker Co. (NYSE:SYK - Free Report) by 79.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,853 shares of the medical technology company's stock after buying an additional 7,922 shares during the quarter. Bryn Mawr Capital Management LLC's holdings in Stryker were worth $6,428,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in the stock. Private Advisor Group LLC boosted its position in shares of Stryker by 0.4% during the 4th quarter. Private Advisor Group LLC now owns 16,027 shares of the medical technology company's stock valued at $5,771,000 after acquiring an additional 60 shares during the last quarter. Good Life Advisors LLC boosted its position in shares of Stryker by 4.0% during the 4th quarter. Good Life Advisors LLC now owns 3,764 shares of the medical technology company's stock valued at $1,355,000 after acquiring an additional 146 shares during the last quarter. Global Retirement Partners LLC boosted its position in shares of Stryker by 14.1% during the 4th quarter. Global Retirement Partners LLC now owns 7,052 shares of the medical technology company's stock valued at $2,539,000 after acquiring an additional 869 shares during the last quarter. DSM Capital Partners LLC boosted its position in shares of Stryker by 358.7% during the 4th quarter. DSM Capital Partners LLC now owns 3,289 shares of the medical technology company's stock valued at $1,184,000 after acquiring an additional 2,572 shares during the last quarter. Finally, Atlas Legacy Advisors LLC bought a new position in shares of Stryker during the 4th quarter valued at approximately $777,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Stock Down 1.0 %

SYK traded down $3.75 on Friday, hitting $382.67. The company had a trading volume of 650,429 shares, compared to its average volume of 1,368,135. The stock has a fifty day moving average price of $377.92 and a 200-day moving average price of $368.21. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The stock has a market capitalization of $146.02 billion, a price-to-earnings ratio of 49.32, a P/E/G ratio of 2.93 and a beta of 0.96.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the business earned $3.46 EPS. Analysts predict that Stryker Co. will post 13.49 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.88%. Stryker's payout ratio is 43.30%.

Insider Transactions at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on SYK shares. StockNews.com downgraded Stryker from a "buy" rating to a "hold" rating in a research report on Thursday, January 30th. Citigroup increased their target price on Stryker from $411.00 to $450.00 and gave the company a "buy" rating in a research report on Wednesday, December 11th. Barclays raised their price target on Stryker from $418.00 to $443.00 and gave the stock an "overweight" rating in a research report on Monday, February 10th. Canaccord Genuity Group raised their price target on Stryker from $420.00 to $435.00 and gave the stock a "buy" rating in a research report on Wednesday, January 29th. Finally, Robert W. Baird raised their price target on Stryker from $378.00 to $405.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Stryker has an average rating of "Moderate Buy" and an average target price of $420.68.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.